Wranik WD. Zielińska D. Sevgur S. Gambold L. 2019. Threats to the value of Health Technology Assessment: Qualitative Evidence from Canada and Poland. Health Policy. 123:191-202
Wranik WD. Skedgel C. Hu M. (2018). Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian Stakeholders. Expert Review of Pharmacoeconomics and Outcomes Research. Online.
Skedgel C. Wranik WD. Hu M. (2018). The relative importance of clinical, economics, patient values and feasibility criteria in cancer drug reimbursement in Canada: A revealed preferences analysis of recommendations of the pan-Canadian Oncology Drug Review 2011-2017. Pharmacoeconomics. 36(4):467-475
Wranik DW. Muir A. Hu M. (2017). Costs of productivity loss due to occupational cancer in Canada: estimation using claims data from Workers’ Compensation Boards. Health Economics Review. 7(1):9
Wranik WD. Gambold L. Hanson N. Levy A. (2016) The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation? International Journal of Health Planning and Management. 32(2):e232-e260